Guardant360 tests 55 genes. This advanced liquid biopsy test is designed to detect various genetic alterations in tumor DNA shed into the bloodstream, offering insights for cancer treatment.
Understanding the Guardant360 Gene Panel
Guardant360® CDx is a qualitative next-generation sequencing-based in vitro diagnostic device that utilizes targeted high-throughput hybridization-based capture technology. It is primarily used for comprehensive genomic profiling in patients with advanced cancer, providing information about specific mutations that can guide therapeutic decisions.
The test comprehensively analyzes a set of genes for different types of genomic alterations:
| Alteration Type | Genes Tested | Description |
|---|---|---|
| Single Nucleotide Variants (SNVs) | 55 genes | Detects changes in a single DNA building block within the gene. |
| Insertions and Deletions (Indels) | 55 genes | Identifies small additions or removals of DNA segments within the gene sequence. |
| Copy Number Amplifications (CNAs) | 2 genes | Detects an increased number of copies of specific genes, which can lead to increased protein production. |
The 2 genes analyzed for copy number amplifications are included within the broader panel of 55 genes that Guardant360 evaluates. This ensures a broad assessment of common and actionable mutations relevant to various cancer types, all from a simple blood draw. The test's utility lies in its ability to provide genetic information quickly and non-invasively, especially when traditional tissue biopsies are not feasible.
